-
Plain language summaries
It’s been a few years (if not decades) since plain language summaries (PLS) took off as a method of disseminating complex scientific findings to non-specialist audience. Why do we have a feeling that we still haven’t got them quite right? While the number of journals offering to publish PLS has increased, the concept remains ill-defined.…
-
A summary of major scientific publishers’ guidelines on the use of LLMs and other genAI in research articles
As more and more authors turn to large language models (LLMs) and other generative artificial intelligence (genAI) tools for writing support, the scientific publishers have responded with a patchwork of guidance that varies considerably across journals and publishers. Here, we rise to the challenge of navigating this complex environment in an attempt to summarise very…
-
Our commitment to the local community
When we founded Parse Medical, an important part of our vision was to make a beneficial contribution to our community and society as a whole. Our business is in medical communications, meaning that through our work we can introduce positive change for many stakeholders: pharmaceutical companies, research organisations, academic institutions, charities, and most importantly patients.…
-
What is your favourite warm-up question?
When you’re planning a medical education symposium, your biggest challenge is keeping your audience engaged: once their attention is lost, it takes a lot of effort to win them back. That’s why, on top of the top-notch scientific content, it’s worth your while to iron out all other factors of success: faculty appeal and chemistry,…
-
Communicating the safety profile of an oncology drug
At the centre of any communication on the adverse event (AE) profile of a new drug lies a fundamental principle: no medication is ever completely safe. Every drug, from over-the-counter paracetamol to cutting-edge biologics, is associated with a specific set of AEs listed on the package insert. Having said that, anticancer drugs exist in a…
